A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

• Drug: CVX-241
  
  0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
  Other Name: PF-05057459
• Drug: CVX-241
  
  1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
  Other Name: PF-05057459
• Drug: CVX-241
  
  3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
  Other Name: PF-05057459
• Drug: CVX-241
  
  6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
  Other Name: PF-05057459
• Drug: CVX-241
  
  12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
  Other Name: PF-05057459
• Drug: CVX-241
  
  15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
  Other Name: PF-05057459
• Drug: CVX-241
  
  18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
  Other Name: PF-05057459
• Drug: CVX-241
  
  25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
  Other Name: PF-05057459

Inclusion Criteria:

• Confirmed solid tumors unresponsive to current therapy or for which there is no standard therapy.
• Stage 2 only: Histologically or cytologically documented EOC or PPC with < or equal to 3 previous anti-cancer therapies, but at least 1 prior platinum containing regimen.
• Adequate coagulation, liver, and renal function.
• Candidate for Dynamic Contrast-Enhanced Magnetic Resonance Imaging [DCE-MRI] evaluation
• Eastern Cooperative Oncology Group [ECOG] performance status of 0 or 1

Exclusion Criteria:

• History of clinically significant toxicity to Vascular Endothelial Growth Factor [VEGF] inhibition.
• Evidence of bleeding problems.
• Uncontrolled hypertension.
• Patients with primary brain cancer and/or non-small cell lung cancer of squamous cell histology